Human Antibodies against a Purified Glucosylceramide fromCryptococcus neoformansInhibit Cell Budding and Fungal Growth
- 1 December 2000
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 68 (12) , 7049-60
- https://doi.org/10.1128/iai.68.12.7049-7060.2000
Abstract
A major ceramide monohexoside (CMH) was purified from lipidic extracts of Cryptococcus neoformans. This molecule was analyzed by high-performance thin-layer chromatography (HPTLC), gas chromatography coupled with mass spectrometry, and fast atom bombardment-mass spectrometry. The cryptococcal CMH is a beta-glucosylceramide, with the carbohydrate residue attached to 9-methyl-4,8-sphingadienine in amidic linkage to 2-hydroxyoctadecanoic acid. Sera from patients with cryptococcosis and a few other mycoses reacted with the cryptococcal CMH. Specific antibodies were purified from patients' sera by immunoadsorption on the purified glycolipid followed by protein G affinity chromatography. The purified antibodies to CMH (mainly immunoglobulin G1) bound to different strains and serological types of C. neoformans, as shown by flow cytofluorimetry and immunofluorescence labeling. Transmission electron microscopy of yeasts labeled with immunogold-antibodies to CMH and immunostaining of isolated cell wall lipid extracts separated by HPTLC showed that the cryptococcal CMH predominantly localizes to the fungal cell wall. Confocal microscopy revealed that the beta-glucosylceramide accumulates mostly at the budding sites of dividing cells with a more disperse distribution at the cell surface of nondividing cells. The increased density of sphingolipid molecules seems to correlate with thickening of the cell wall, hence with its biosynthesis. The addition of human antibodies to CMH to cryptococcal cultures of both acapsular and encapsulated strains of C. neoformans inhibited cell budding and cell growth. This process was complement-independent and reversible upon removal of the antibodies. The present data suggest that the cryptococcal beta-glucosylceramide is a fungal antigen that plays a role on the cell wall synthesis and yeast budding and that antibodies raised against this component are inhibitory in vitro.Keywords
This publication has 99 references indexed in Scilit:
- Blocking Adherence of Candida albicans to Buccal Epithelial Cells by Yeast Glycolipids, Yeast Wall Lipids and Lipids from Epithelial Cells./Adhärenzhemmung von Candida albicans an Mundschleimhaut-Epithelzellen durch Hefe-Glykolipide, Hefezellwand-Lipide uMycoses, 2009
- Comparative analysis of ceramide structural modification found in fungal cerebrosides by electrospray tandem mass spectrometry with low energy collision-induced dissociation of Li+ adduct ionsRapid Communications in Mass Spectrometry, 2000
- β‐1,6‐Glucan synthesis in Saccharomyces cerevisiaeMolecular Microbiology, 2000
- The β-1,6-glucan containing side-chain of cell wall proteins ofSaccharomyces cerevisiaeis bound to the glycan core of the GPI moietyFEMS Microbiology Letters, 1996
- Cryptococcus neoformans: Paradigm for the Role of Antibody Immunity Against Fungi?Zentralblatt für Bakteriologie, 1996
- Paracoccidioides brasiliensis Expresses Both Glycosylphosphatidylinositol-Anchored Proteins and a Potent Phospholipase CExperimental Mycology, 1995
- Ultrastructural study ofCryptococcus neoformans by quick-freezing and deep-etching methodMycopathologia, 1993
- Modulation of cell growth and differentiation by ceramideFEBS Letters, 1992
- Monoclonal antibody to galactosylceramide: discrimination of structural difference in the ceramide moietyFEBS Letters, 1989
- Soluble and insoluble glucans from different cell types of the human pathogen Sporothrix schenckiiExperimental Mycology, 1979